Medtil-CV Tablet is a combination antibiotic formulation containing Cefuroxime 500 mg and Clavulanic Acid 125 mg, designed to treat a broad spectrum of bacterial infections. Cefuroxime, a second-generation cephalosporin, exhibits bactericidal activity by inhibiting bacterial cell wall synthesis, effectively targeting both Gram-positive and Gram-negative organisms. Clavulanic Acid acts as a beta-lactamase inhibitor, preventing enzymatic degradation of Cefuroxime by beta-lactamase-producing bacteria, thereby enhancing its efficacy against resistant strains. Medtil-CV is indicated for the management of respiratory tract infections, urinary tract infections, skin and soft tissue infections, and other susceptible bacterial infections. The combination offers improved coverage against beta-lactamase-producing pathogens, making it suitable for complicated infections where resistance is a concern. It is administered orally and should be taken as prescribed by a healthcare professional, with dosage adjustments based on infection severity and patient renal function. Common adverse effects may include gastrointestinal disturbances, hypersensitivity reactions, and mild hematologic changes. Caution is advised in patients with a history of penicillin or cephalosporin allergy. Medtil-CV Tablet provides a potent therapeutic option in combating resistant bacterial infections, ensuring effective clinical outcomes when used appropriately.